Tecan outlines long-term automation strategy, shares trade steadily on SIX

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 12:05.

Tecan Group AG (CH0012100191) remains a key Swiss laboratory automation and diagnostics name, with its shares trading on SIX Swiss Exchange alongside peers such as Roche and Straumann. The stock currently reflects a long-term strategy built around recurring revenues and automation demand in life sciences.

Strategy in lab automation

Tecan focuses on modular robotic platforms, liquid-handling systems and integrated workflows that automate sample preparation and analysis across genomics, proteomics and clinical diagnostics. The company positions these systems as productivity tools for pharmaceutical, biotech and clinical laboratories.

A core objective is to deepen integration with customers’ digital infrastructures and laboratory information systems, which supports higher switching costs and long-lived equipment cycles. In parallel, Tecan seeks to increase the share of consumables and services, which typically deliver more stable and predictable margins than one-off hardware sales.

Long-term profile and peers

Over the long term, Tecan’s growth case is tied to rising test volumes, more complex assays and the trend toward standardized, automated workflows in regulated environments. Swiss-listed healthcare and life-science equipment peers, including Roche and Lonza, follow similar structural drivers of automation and outsourcing in R&D and manufacturing.

Investors commonly compare Tecan with global automation specialists such as Thermo Fisher Scientific and Danaher in terms of recurring revenue mix, R&D intensity and exposure to biopharma capex cycles. The stock’s risk profile is influenced by customers’ investment budgets and regulatory demands in diagnostics markets.

How the company earns money

Tecan generates revenues from selling automation platforms, detection instruments, reagents, plastic consumables and service contracts to diagnostics companies, research institutions and pharmaceutical groups. An important pillar is OEM solutions, where Tecan develops and manufactures instruments and components that are sold under partners’ brands.

Where the stock trades today

The Tecan shares (CH0012100191) trade on SIX Swiss Exchange in Zurich, quoted in Swiss francs.

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. All data have been researched carefully but without any guarantee of completeness or accuracy.